SCHEMBL7934900

SCHEMBL7934900

CCCCCCCCCCc1ccc(-c2ccc(O)cc2)cc1

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 3/20 0.88
ESR1 P03372 2/20 0.88
ADRA2A P08913 2/20 0.88
ADORA3 P0DMS8 2/20 0.88
TACR2 P21452 2/20 0.88
SLC6A2 P23975 2/20 0.88
SLC6A4 P31645 2/20 0.88
SLC6A3 Q01959 2/20 0.88
ALDH1A1 P00352 2/20 0.88
HSD17B10 Q99714 2/20 0.88
KDM4E B2RXH2 1/20 0.88
LMNA P02545 1/20 0.88
SHBG P04278 1/20 0.88
TP53 P04637 1/20 0.88
CYP3A4 P08684 1/20 0.88
HSPD1 P10809 1/20 0.88
ADRB3 P13945 1/20 0.88
HTR2C P28335 1/20 0.88
HSPE1 P61604 1/20 0.88
HIF1A Q16665 1/20 0.88

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9227876 1.00 PTGS2 (0.88) PTGS2ESR1ADRA2AADORA3TACR2
SCHEMBL982001 1.00 PTGS2 (0.88) PTGS2ESR1ADRA2AADORA3TACR2
SCHEMBL28177799 1.00 PTGS2 (0.88) PTGS2ESR1ADRA2AADORA3TACR2
SCHEMBL981447 1.00 PTGS2 (0.88) PTGS2ESR1ADRA2AADORA3TACR2
SCHEMBL984111 1.00 PTGS2 (0.88) PTGS2ESR1ADRA2AADORA3TACR2
SCHEMBL981893 1.00 PTGS2 (0.88) PTGS2ESR1ADRA2AADORA3TACR2
SCHEMBL982373 1.00 PTGS2 (0.88) PTGS2ESR1ADRA2AADORA3TACR2
SCHEMBL982418 0.98 PTGS2 (0.84) PTGS2ESR1ADRA2AADORA3TACR2
SCHEMBL7253630 0.98 PTGS2 (0.84) PTGS2ESR1ADRA2AADORA3TACR2
SCHEMBL19497894 0.96 PTGS2 (0.81) PTGS2ESR1ADRA2AADORA3TACR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-8231468-A None JP disclosed
CN-106946709-B Polymerizable liquid crystal compound, composition for optical film, and optical film, compensation film, antireflection film and display device 三星电子株式会社 2021-11-12 CN disclosed
US-10071949-B2 Polymerizable liquid crystal compound, composition for optical film, and optical film, compensation film, antireflective film, and display device including the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2018-09-11 US disclosed
EP-3187566-B1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND, COMPOSITION FOR OPTICAL FILM, AND OPTICAL FILM, COMPENSATION FILM, ANTIREFLECTIVE FILM, AND DISPLAY DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO LTD (KR) 2018-04-18 EP disclosed
EP-3187566-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND, COMPOSITION FOR OPTICAL FILM, AND OPTICAL FILM, COMPENSATION FILM, ANTIREFLECTIVE FILM, AND DISPLAY DEVICE INCLUDING THE SAME Samsung Electronics Co., Ltd (KR) 2017-07-05 EP disclosed
US-20170183286-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND, COMPOSITION FOR OPTICAL FILM, AND OPTICAL FILM, COMPENSATION FILM, ANTIREFLECTIVE FILM, AND DISPLAY DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2017-06-29 US disclosed
CN-103467730-B Carbamate compounds Asahi Kasei Chemical K. K. (JP) 2015-12-23 CN disclosed
CN-101868445-B Method for producing isocyanate and aromatic hydroxy compound ASAHI CHEMICAL CORP 2014-06-18 CN disclosed
CN-101652344-B Method for production of isocyanate using composition comprising carbamic acid ester and aromatic hydroxy compound, and composition for transport or storage of carbamic acid ester ASAHI CHEMICAL CORP JP 2014-06-04 CN disclosed
CN-103467730-A Carbamate compound ASAHI KASEI CHEMICAL CORP 2013-12-25 CN disclosed
EP-0422996-A2 Liquid crystal compound Showa Shell Sekiyu Kabushiki Kaisha (JP) 1991-04-17 EP disclosed
US-4973738-A Liquid crystal compounds having naphthalene nucleus SHOWA SHELL SEKIYU K.K. (JP) 1990-11-27 US disclosed
EP-0393613-A1 Mesomorphic compound, liquid crystal composition containing same and liquid crystal device using same CANON KABUSHIKI KAISHA (JP) 1990-10-24 EP disclosed
EP-0364923-A2 Mesomorphic compound, liquid crystal composition containing same and liquid crystal device using same CANON KABUSHIKI KAISHA (JP) 1990-04-25 EP disclosed
US-4911863-A Ferroelectric; mixture of compounds containing aromatic ester THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) 1990-03-27 US disclosed
EP-0339987-A2 Liquid crystal compounds having naphthalene nucleus Showa Shell Sekiyu Kabushiki Kaisha (JP) 1989-11-02 EP disclosed
EP-0310620-A1 CHIRAL LIQUID CRYSTAL COMPOUNDS. SECR DEFENCE BRIT (GB) 1989-04-12 EP disclosed
EP-0263843-A1 LIQUID CRYSTAL COMPOUNDS, MIXTURES AND DEVICES. SECR DEFENCE BRIT (GB) 1988-04-20 EP disclosed
WO-1987007890-A2 CHIRAL LIQUID CRYSTAL COMPOUNDS THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNI (GB) 1987-12-30 WO disclosed
WO-1987005012-A2 LIQUID CRYSTAL COMPOUNDS, MIXTURES AND DEVICES THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNI (GB) 1987-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10071949-B2 Polymerizable liquid crystal compound, composition for optical film, and optical film, compensation film, antireflective film, and display device including the same AQP1, TCOF1, SFXN1 PTGS2 4504/4885ESR1 4242/4885ADRA2A 4203/4885
US-20170183286-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND, COMPOSITION FOR OPTICAL FILM, AND OPTICAL FILM, COMPENSATION FILM, ANTIREFLECTIVE FILM, AND DISPLAY DEVICE INCLUDING THE SAME AQP1, TCOF1, SFXN1 PTGS2 4504/4885ESR1 4242/4885ADRA2A 4203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.